Tvaster Genkalp

Tvaster Genkalp is a molecular diagnostics company headquartered in Chennai, India, that specializes in precision oncology through advanced epigenetic screening. The company utilizes its proprietary Sequencing Independent Quantitative Methylation Profiling (qSIMP) platform to develop non-invasive liquid biopsy tests for early cancer detection and monitoring. Its lead product, Episcreen Liver, is designed for the early detection of hepatocellular carcinoma (HCC) and has demonstrated significantly higher sensitivity compared to traditional biomarkers like alpha-fetoprotein. Beyond liver cancer, the company is advancing a pipeline of diagnostic tools for cholangiocarcinoma and chemotherapy resistance in pediatric hepatoblastoma. Tvaster Genkalp aims to improve patient outcomes by providing oncologists with high-accuracy genetic and epigenetic data to inform personalized treatment decisions. The company is currently scaling its commercial operations across India following successful clinical validation of its core technology.